KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Short-term Investments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Short-term Investments data on record, last reported at $5.5 billion in Q4 2025.

  • For Q4 2025, Short-term Investments fell 15.9% year-over-year to $5.5 billion; the TTM value through Dec 2025 reached $5.5 billion, down 15.9%, while the annual FY2025 figure was $5.5 billion, 15.9% down from the prior year.
  • Short-term Investments reached $5.5 billion in Q4 2025 per REGN's latest filing, down from $5.9 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $8.1 billion in Q4 2023 and bottomed at $1.8 billion in Q2 2021.
  • Average Short-term Investments over 5 years is $5.4 billion, with a median of $5.5 billion recorded in 2025.
  • Peak YoY movement for Short-term Investments: surged 126.87% in 2022, then plummeted 33.57% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $2.4 billion in 2021, then soared by 96.86% to $4.6 billion in 2022, then skyrocketed by 75.02% to $8.1 billion in 2023, then decreased by 19.6% to $6.5 billion in 2024, then fell by 15.9% to $5.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $5.5 billion in Q4 2025, $5.9 billion in Q3 2025, and $5.5 billion in Q2 2025.